Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Vor Biopharma is raising $110,124,989.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Robert Ang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vor Biopharma

Vor Biopharma is pioneering engineered hematopoietic stem cells (eHSCs) to dramatically change the treatment paradigm for hematological cancers. Vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. Vor is based in Cambridge, Mass. and has a broad intellectual property base including in-licenses from Columbia University. Vor was founded by Dr. Mukherjee and PureTech Health and is supported by leading investors including 5AM Ventures and RA Capital Management, Johnson & Johnson Innovation JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research and Osage University Partners.

To learn more about Vor Biopharma, visit http://www.vorbiopharma.com/

Contact:
Robert Ang, Chief Executive Officer
617-655-6580
https://www.linkedin.com/in/robert-ang-069746/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved